Clinical Trial Update: Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a carboplatin/gemcitabine hydrochloride/berzosertib combination in patients with recurrent or metastatic ovarian, fallopian tube, or pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Berzosertib (berzosertib)
• CARBOPLATIN (Carboplatin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-02